UBS Asset Management Americas Inc. bought a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,763,012 shares of the company’s stock, valued at approximately $105,552,000.
Other large investors have also modified their holdings of the company. FIL Ltd purchased a new stake in Maravai LifeSciences during the fourth quarter valued at about $18,467,000. Alyeska Investment Group L.P. purchased a new position in shares of Maravai LifeSciences in the fourth quarter worth about $29,744,000. Jefferies Group LLC bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at about $2,259,000. Jennison Associates LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at about $7,444,000. Finally, Victory Capital Management Inc. bought a new position in Maravai LifeSciences during the 4th quarter worth approximately $2,946,000.
MRVI has been the topic of several recent analyst reports. Robert W. Baird initiated coverage on shares of Maravai LifeSciences in a report on Tuesday, December 15th. They issued an “outperform” rating and a $31.00 target price on the stock. Zacks Investment Research lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Thursday. Morgan Stanley increased their target price on shares of Maravai LifeSciences from $35.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, March 9th. William Blair initiated coverage on Maravai LifeSciences in a research note on Tuesday, December 15th. They issued an “outperform” rating on the stock. Finally, The Goldman Sachs Group assumed coverage on Maravai LifeSciences in a research report on Tuesday, December 15th. They set a “buy” rating and a $38.00 price target for the company. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $38.33.
Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Monday, March 1st. The company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.02. The firm had revenue of $98.35 million during the quarter, compared to analysts’ expectations of $87.48 million. On average, equities research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post 0.36 earnings per share for the current year.
Maravai LifeSciences Company Profile
There is no company description available for Maravai LifeSciences Holdings Inc
Further Reading: Short Selling
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI).
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.